Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection

Zeuzem, S; Foster, GR; Wang, S; Asatryan, A; Gane, E; Feld, JJ; Asselah, T; Bourliere, M; Ruane, PJ; Wedemeyer, H; Pol, S; Flisiak, R; Poordad, F; Chuang, WL; Stedman, CA; Flamm, S; Kwo, P; Dore, GJ; Sepulveda-Arzola, G; Roberts, SK; Soto-Malave, R;

Zeuzem, S (reprint author), Univ Hosp Frankfurt, Dept Med, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.

NEW ENGLAND JOURNAL OF MEDICINE, 2018; 378 (4): 354

Abstract

BACKGROUND Glecaprevir and pibrentasvir are direct-acting antiviral agents with pangenotypic activity and a high barrier to resistance. We evaluated t......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索